Johnson & Johnson (JNJ)
Johnson & Johnson operates in the Pharmaceutical Preparations industry (SIC 2834). The company develops and markets prescription medicines and medical technologies across areas such as oncology, immunology, neuroscience, cardiovascular disease, surgery, and vision care.
Headquartered in New Brunswick, New Jersey, USA. Fiscal year ends in late December. Filing category: Large accelerated filer.
| Ticker | JNJ |
|---|
| Company | Johnson & Johnson |
|---|
| Exchange | NYSE |
|---|
| Headquarters | NEW BRUNSWICK, NJ |
|---|
Income statement — period ending 2026-06-28
| Comprehensive Income (Loss), Net of Tax, Attributable to Parent | $6,414,000,000 |
|---|
| Cost of Goods and Services Sold | $8,051,000,000 |
|---|
| Earnings Per Share, Basic | 2 USD/shares |
|---|
| Earnings Per Share, Diluted | 2 USD/shares |
|---|
| Gross Profit | $17,259,000,000 |
|---|
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | $6,747,000,000 |
|---|
| Income Tax Expense (Benefit) | $1,213,000,000 |
|---|
| InterestExpenseNonoperating | $281,000,000 |
|---|
| Investment Income, Interest | $219,000,000 |
|---|
| Net Income (Loss) Attributable to Parent | $5,534,000,000 |
|---|
| Other Nonoperating Income (Expense) | -$331,000,000 |
|---|
| Restructuring Charges | $34,000,000 |
|---|
| Revenue from Contract with Customer, Excluding Assessed Tax | $25,310,000,000 |
|---|
| Selling, General and Administrative Expense | $6,432,000,000 |
|---|
| Share-based Payment Arrangement, Noncash Expense | $758,000,000 |
|---|
| Weighted Average Number of Shares Outstanding, Diluted | 2,440,100,000 shares |
|---|
| Weighted Average Number of Shares Outstanding, Basic | 2,407,400,000 shares |
|---|
Sourced from SEC EDGAR/XBRL filings via StockSpectro.
View full interactive research on StockSpectro